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Low-dose antithymocyte globulin (ATG) plus pegylated
granulocyte colony-stimulating factor (G-CSF) preserves
b-cell function for at least 12 months in type 1 diabetes.
Herein, we describe metabolic and immunological pa-
rameters 24 months following treatment. Patients with
established type 1 diabetes (duration 4–24 months) were
randomized to ATG and pegylated G-CSF (ATG+G-CSF)
(N = 17) or placebo (N = 8). Primary outcomes included
C-peptide area under the curve (AUC) following a mixed-
meal tolerance test (MMTT) and flow cytometry.
“Responders” (12-month C-peptide ‡ baseline), “super
responders” (24-month C-peptide ‡ baseline), and “non-
responders” (12-month C-peptide < baseline) were
evaluated for biomarkers of outcome. At 24 months,
MMTT-stimulated AUC C-peptide was not significantly
different in ATG+G-CSF (0.49 nmol/L/min) versus placebo
(0.29 nmol/L/min). Subjects treated with ATG+G-CSF
demonstrated reduced CD4+ T cells and CD4+/CD8+ T-cell
ratio and increased CD16+CD56hi natural killer cells (NK),
CD4+ effector memory T cells (Tem), CD4+PD-1+ central
memory T cells (Tcm), Tcm PD-1 expression, and neu-
trophils. FOXP3+Helios+ regulatory T cells (Treg) were
elevated in ATG+G-CSF subjects at 6, 12, and 18 but
not 24 months. Immunophenotyping identified differential
HLA-DR expression on monocytes and NK and altered
CXCR3 and PD-1 expression on T-cell subsets. As such,
a group of metabolic and immunological responders
was identified. A phase II study of ATG+G-CSF in pa-
tients with new-onset type 1 diabetes is ongoing and
may support ATG+G-CSF as a prevention strategy in
high-risk subjects.
Type 1 diabetes results from a period of chronic auto-
immunity contributing to pancreatic b-cell death and
dysfunction (1), and despite decades of investigation, a
cure for the disease remains elusive. The most common
clinical research strategies for intervention involve the
administration of an immunomodulatory or immuno-
suppressive agent to potentially slow or halt the autoim-
mune disease process and preserve remaining b-cell mass
(2,3). Though some monotherapies have shown promise,
the beneficial effects have generally been limited and short
lived.
In recent years, combination therapy has been heralded
as a means to conceivably elicit therapeutic synergism and
target multiple aspects of the complex pathology (2,4). In-
deed, perhaps the most aggressive protocol tested to date
utilized autologous nonmyeloablative stem cell transplant
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involving the administration of cyclophosphamide along
with the stem cell mobilizing agent, granulocyte colony-
stimulating factor (G-CSF), and high doses of antithymo-
cyte globulin (ATG) for leukocyte depletion. Despite the
severe side effects associated with treatment, nearly all
patients experienced a period of type 1 diabetes remission
and were able to temporarily stop exogenous insulin ad-
ministration, some for 4 years or longer, representing a
clear breakthrough in the field (5–8).
Considering the importance of minimizing therapeutic
risks relative to clinical benefit in patients with type 1
diabetes, we have attempted to deconstruct this cocktail
and determine whether a safer approach could be defined
with comparable efficacy. The Study of Thymoglobulin to
Arrest Type 1 Diabetes (START) trial, with a higher dose
of ATG alone (6.5 mg/kg), did not achieve the primary
end point; however, in post hoc analysis, older subjects
maintained stable b-cell function out to 2 years (9,10).
Likewise, G-CSF alone (6 mg every 2 weeks 3 12 weeks)
did not have an effect (11). However, our previous work
in NOD mice suggested that lower-dose ATG coupled with
G-CSF mediates diabetes reversal via immunomodulatory
effects including increased regulatory T cell (Treg) fre-
quency and hematopoietic mobilization. We recently dem-
onstrated that the combination of low-dose ATG (2.5 mg/kg)
and pegylated G-CSF (ATG+G-CSF) preserves C-peptide
for at least 12 months in subjects with established type
1 diabetes (4–24 months duration) (12). Herein, we re-
port 2-year clinical outcomes and mechanistic data from
our study of low-dose ATG and G-CSF in patients with
established type 1 diabetes.
RESEARCH DESIGN AND METHODS
Study Patients
For this single-blinded, randomized, placebo-controlled study,
screening and enrollment was performed at three study sites
(University of California, San Francisco [UCSF], University of
Colorado [UC], and University of Florida [UF]) as previously
described (12). Briefly, patients aged 12–45 years with type
1 diabetes of duration.4 months to,2 years and minimum
peak C-peptide of 0.1 nmol/mL following a 4-h mixed-meal
tolerance test (MMTT) were eligible for the study. Patients
with an allergy to ATG or G-CSF, prior treatment with ATG,
immunodeficiency, or chronic infection (including hepatitis B
or C, or HIV) were not eligible.
Study Design
Within 8 weeks of the screening visit, eligible subjects
were randomized in a 2:1 ratio to receive ATG (Thymo-
globulin; Sanofi) (0.5 mg/kg on day 1 and 2 mg/kg on day
2 via intravenous infusion for total dose of 2.5 mg/kg)
and pegylated G-CSF (Neulasta; Amgen) (6 mg via sub-
cutaneous injection administered every 2 weeks for 6 doses)
or placebo. Subjects were hospitalized for the first 2 days
during the ATG or placebo infusions and the first G-CSF or
placebo injection. Prior to and 12 h after ATG infusion, pa-
tients were administered methylprednisolone (0.25 mg/kg),
and placebo infusions and injections were given on the
same schedule to patients randomized to the placebo group.
All subjects in both groups received acetaminophen and
diphenhydramine prior to ATG or placebo infusion.
ATG+G-CSF–treated subjects were given trimethoprim-
sulfamethoxazole and acyclovir for the first 3 months of
treatment as antimicrobial prophylaxis while placebo-
treated subjects received placebo prophylaxis. Throughout
the study, all subjects continued intensive diabetes man-
agement with their personal diabetes physicians.
Study Assessments and Laboratory Procedures
Physical examination was performed and metabolic and
immunological samples obtained at baseline; weeks 1, 2,
4, 6, 8 and 10; and months 3, 6, 9, 12, 18, and 24 from
the time of enrollment. The following were performed at
each visit. Glycated hemoglobin (HbA1c) was measured via
DCA2000 or DCA Vantage Analyzer (Siemens Healthcare
Diagnostics, Malvern, PA). MMTT (Boost, 6 mL/kg, max-
imum 360 mL) was administered, serum C-peptide was
measured at the Northwest Lipid Research Laboratories,
and 2-h C-peptide area under the curve (AUC) was calcu-
lated. Autoantibodies against glutamic acid decarboxylase,
insulinoma-associated protein 2, insulin, and zinc trans-
porter 8 were measured via radioimmunoassay at the Bar-
bara Davis Center (13–15). Flow cytometric analysis of
peripheral blood immune cell subsets was performed as
described below. Adverse events (AEs) were recorded in
accordance with Common Terminology Criteria for Adverse
Events classifications (version 4.0; http://evs.nci.nih.gov/
ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_
5x7.pdf).
Flow Cytometry
Fresh whole blood was shipped overnight from UC and
UCSF to the UF site, and samples drawn at the UF clinic
were rested while rocking for 24 h (rested to match
shipped samples). An aliquot of whole blood (24-h rested)
was stained using two antibody panels, and the remaining
samples were stored as cryopreserved peripheral blood
mononuclear cells (PBMCs). The first panel for whole
blood included the surface markers CD3, CD4, CD8, and
CD19. The second panel included surface markers CD4,
CD25, CD45RA, and CD45RO, followed by intracellular
staining for the canonical Treg transcription factors
FOXP3 and Helios. Whole blood (100 mL) was labeled
with surface antibodies at ambient temperature for
20 min. Red blood cells were then lysed with BD FACS lysing
solution (BD Biosciences, San Jose, CA) and subsequently
washed with 0.9% BSA 13 Dulbecco’s PBS buffer. Follow-
ing red blood lysis, the first panel was quantified with a
BD Accuri C6 flow cytometer (BD Biosciences) while the
second panel was fixed, permeabilized, and labeled with
intracellular antibodies using a FOXP3 Fix/Perm buffer
set (Biolegend, San Diego, CA), and data were quantified
using a BD LSRFortessa flow cytometer (BD Biosciences)
with data analyzed with FCS Express software (De Novo,
Glendale, CA).
3766 ATG+G-CSF 2-Year Outcomes in Type 1 Diabetes Diabetes Volume 65, December 2016
Cryopreserved PBMCs were batch processed and thawed,
washed into complete RPMI, and incubated with 100 units
DNase (Roche, Indianapolis, IN) at 37°C for 15–30 min.
Cells were then labeled with LIVE/DEAD Yellow Viability
Dye (Invitrogen, Carlsbad, CA), followed by surface labeling
with five antibody panels designed to provide an assess-
ment of both innate and adaptive immune cell subsets.
The panels were emulated from Maecker et al. (16) and
consist of a B-cell subset panel (CD3, CD19, CD20, CD24,
CD27, CD38, and IgD), an innate cell panel (CD3, CD11c,
CD14, CD16, CD19, CD20, CD56, CD123, and HLA-DR), a
naive and memory T-cell panel (CD3, CD4, CD8, CD38,
CD45RA, CD197, and HLA-DR), an effector T-cell subset
panel (CD3, CD4, CD38, CD45RO, CD183 [CXCR3], CD196
[CCR6], and HLA-DR), and a Treg panel (CD3, CD4, CD25,
CD45RO, CD127, CD194 [CCR4], and HLA-DR). In addition,
a T follicular helper cell (Tfh) panel (CD3, CD4, CD45RA,
CD183, CD196, CD197 [CCR7], and CD279 [PD-1]) was
designed to assess precursor Tfh (17) and memory Tfh (18).
Specific antibody clones and suppliers are listed in Sup-
plementary Table 1, and immune cell subset definitions
are listed in Supplementary Table 2. Stained cells were an-
alyzed using a BD LSRFortessa flow cytometer and FlowJo
data analysis software (Ashland, OR).
End Points
The primary outcome was MMTT 2-h C-peptide AUC
change from baseline. Secondary outcomes included change
in HbA1c, insulin dose, and AEs, as well as immunologi-
cal parameters including CD16+CD56hi natural killer cell
(NK) frequency, CD4+ effector memory T-cell (Tem) fre-
quency, CD4+PD-1+ central memory T-cell (Tcm) frequency,
Tcm PD-1 mean fluorescence intensity (MFI), neutrophil
count, CD4+ T-cell frequency, CD4+/CD8+ T-cell ratio, and
FOXP3+Helios+ Treg frequency. Markers used to identify
immune cell subsets are defined in Supplementary Table
2. Within the ATG+G-CSF treatment group, secondary
outcome measures were compared between 12-month
responders (previously defined as patients with 12-month
MMTT 2-h C-peptide AUC $ baseline values [12]) and
nonresponders, as well as between 24-month super re-
sponders (patients with 24-month MMTT 2-h C-peptide
AUC $ baseline values) and non–super responders.
Data Collection and Analysis
Data were collected at each study site and consolidated
using the Clinical and Translational Research Informatics
Program hosted at UF. Statistical analysis was performed
using the open source software package R (version 3.1.0)
by fitting an ANCOVA model with the outcome being the
change of 2-h C-peptide AUC from baseline at 12, 18, and
24 months, and the baseline 2-h AUC is included as an
independent variable. Specifically, the analysis used the
2-h AUC, i.e., Yijk for subject j at treatment arm i at mea-
surement time point k (e.g., 12-, 18-, and 24-month)
changes from baseline measurement, i.e., Yij0 as the out-
comes and fit the following model: E(Yijk) = a0 + a1 Yij0 +
a2 I(trtj = 1) where I is an indicator function and trt = 1
represents the drug treatment arm for the subject. Sec-
ondary outcomes including metabolic and flow cytometry
data were compared using Satterwthaite-corrected t test,
unpaired t test, two-way ANOVA with Sidák post hoc
correction, or the nonparametric Mann-Whitney test. Spear-
man correlation was used to investigate the potential
relationship between D C-peptide AUC and flow cytometry
data. Graphs were generated using GraphPad Prism soft-
ware version 6 (La Jolla, CA). Heat maps were generated
in the R programming syntax (version 3.2.4) modeling the
baseline and longitudinal changes of the examined parame-
ters (cell frequency percentages and MFI fold change) of
the study groups (i.e., 12-month responders, 24-month
super responders, and nonresponders). Significance was de-
fined as P , 0.05.
Study Approval
This study was granted an investigational new drug
permit (IND 107185) and was conducted according to
the guidelines for good clinical practice and the Declara-
tion of Helsinki with the approval of institutional review
boards at UF, UCSF, and UC. Written informed consent
and in the case of minors, assent, was obtained from each
participant prior to study inclusion.
RESULTS
Patients
Patient screening, enrollment, and baseline characteris-
tics were previously reported (12). Briefly, of 37 subjects
screened, 25 were eligible and enrolled using 2:1 random-
ization so that N = 17 subjects were randomly assigned to
receive ATG+G-CSF and N = 8 received placebo. Demo-
graphic as well as baseline metabolic and immunological
measures were comparable between the two groups (12).
One subject receiving ATG+G-CSF dropped out of the study
following the 6-month visit. For all findings reported below,
sex and ethnicity were not found to affect study outcomes.
b-Cell Function
MMTT-stimulated 2-h C-peptide peak and AUC were
comparable at baseline for ATG+G-CSF and placebo treat-
ment groups. We previously demonstrated significantly
greater C-peptide response in ATG+G-CSF–treated ver-
sus placebo-treated subjects for both 2-h AUC at 12
months following therapy and the change in 2-h AUC
from baseline to 12 months (12); although differences
still persisted at 18 and 24 months, they were no longer
statistically significant likely because of the small num-
bers in each group (Fig. 1A and B and Table 1). Interest-
ingly, when subjects were further segregated by diabetes
duration (,1 year vs. $1 year) at study enrollment, there
was a trend toward higher peak C-peptide in ATG+G-CSF–
treated versus placebo-treated subjects with disease dura-
tion .1 year (P = 0.09) (Table 2). We found no significant
differences in change in insulin dose or HbA1c levels (base-
line to 24 months or 12 to 24 months) in ATG+G-CSF–
treated compared with placebo-treated subjects (Table 1).
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Responders Versus Nonresponders
Within the ATG+G-CSF treatment group, we had previously
defined responders as those with MMTT-stimulated 2-h
C-peptide AUC at the 12 month time point equal to or
above baseline values. Nine (56.3%) were responders, and
seven (43.8%) were not (compared with 1 of 8 [12.5%] in
the placebo-treated group) (12). Using this definition, we
found that compared with nonresponders, responders still
exhibited a trend toward greater capacity for C-peptide se-
cretion at 24 months, although the difference was no longer
statistically significant (mean difference 0.28 nmol/L/min,
P = 0.088) (Fig. 1B and C and Table 1). Four ATG+G-CSF–
treated subjects maintained MMTT-stimulated C-peptide
AUC equal to or above mean baseline values even at the
24-month time point (super responders) while all remain-
ing subjects (both ATG+G-CSF–treated and control sub-
jects) had fallen below baseline C-peptide AUC levels (Fig.
1B and D). One of these four was considered a nonre-
sponder at the 12-month time point but improved over
months 12–24 (Fig. 1B, dashed lines).
Clinical Characteristics of Super Responders
For 24-month super responders, the change in HbA1c
from the 12 to 24 month time points was 20.2% 6 0.6
(mean 6 SD) vs. 1.0% 6 2.6 in non–super responders,
although the difference was not statistically significant
(P = 0.18, two-tailed Mann-Whitney test). The change in daily
Figure 1—ATG+G-CSF combination therapy preserves b-cell function for at least 12 months in a subset of responders and for at least
24 months in a small group of super responders. A: C-peptide AUC for ATG+G-CSF–treated (black circles; N = 16) vs. placebo-treated
(gray squares; N = 8) subjects over time (mean 6 SD). C-peptide AUC was significantly higher in ATG+G-CSF subjects at 12 months (P =
0.05) (12) but not at 18 or 24 months (P = 0.11 and P = 0.13, respectively, for Δ AUC). B: Within the ATG+G-CSF treatment group,
subjects were classified according to 12-month MMTT 2-h C-peptide AUC as responders (blue; N = 9; AUC $ baseline at 12 months) and
nonresponders (orange; N = 7; AUC < baseline at 12 months). Individual MMTT 2-h C-peptide AUC values are shown for responders,
nonresponders, and placebo subjects (gray). Subjects with AUC $ baseline at 24 months were classified as super responders (dashed
lines; N = 4; 3/4 were 12-month responders and 1/4 was a 12-month nonresponder). C: Responders (blue) demonstrated a trend toward
greater Δ C-peptide AUC at 24 months after time of enrollment while nonresponders (orange) resembled placebo control subjects (gray; P =
0.09; mean 6 SD). D: Super responders (green; N = 4) demonstrated a trend toward greater Δ C-peptide AUC compared with non–super
responders (gray; N = 12; P = 0.29; mean 6 SD) who were comparable to placebo-treated subjects (black) at 24 months.
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insulin requirements from 12 to 24 months was compara-
ble between super responders (0.09 6 0.12 units/kg/day)
and non–super responders (0.08 6 0.31 units/kg/day,
P = 0.94). The majority of subjects (7/9 [78%] 12-month
responders, 6/7 [86%] 12-month nonresponders) adminis-
tered insulin via injection rather than pump, and few used
a continuous glucose monitor (CGM) (1/9 [11%] responders,
0/7 nonresponders), as documented at the 12-month visit.
Of the four 24-month super responders, three used a pump
to administer insulin and one used injections; one super
responder also used a CGM. None of these four subjects
altered the mode of insulin delivery (pump) or the use of
a CGM between the 12- and 24-month visits. Long-term
preservation of b-cell function in super responders does
not appear to be attributable solely to more rigorous blood
glucose management; however, because of the small sample
size (N = 4 super responders), we cannot definitively de-
termine the relationship between C-peptide secretory capac-
ity and glycemic control.
Complete Blood Count and Flow Cytometry
When compared with control subjects, subjects treated
with ATG+G-CSF had significantly reduced CD4+ T-cell
frequencies (P , 0.01) (Supplementary Fig. 1 and Fig.
2A) and a trend toward increased CD8+ T-cell frequencies
(P = 0.06) (Supplementary Fig. 1 and Fig. 2B), leading to
significantly reduced CD4+/CD8+ T-cell ratios (P , 0.01)
(Fig. 2C). These observations remained consistent over time,
even at 24 months following therapy. FOXP3+Helios+ Treg
frequency was elevated in ATG+G-CSF subjects at 6, 12,
and 18 months (P , 0.05), but the differences were no
longer statistically significant 24 months from the time of
enrollment (P = 0.23) (Supplementary Fig. 2 and Fig. 2D).
Additionally, CD4+ Tem (Fig. 2E), CD16+CD56hi NK (Fig.
2F), and CD4+PD-1+ Tcm frequencies (Fig. 2G), as well as
Tcm PD-1 expression levels (Fig. 2H) and neutrophil counts
(Fig. 2I), were significantly elevated in ATG+G-CSF–treated
subjects compared with those that received placebo, even
24 months from the time of enrollment. Together these
data suggest that many of the immunomodulatory effects
of combination treatment with ATG+G-CSF are persistent
well beyond the therapeutic window, suggesting long-term
immunoregulation contributes toward the preservation of
residual b-cell function.
We further assessed the flow cytometric data for indica-
tions of immunological responders versus nonresponders.
Our data indicated super responders had a transient in-
crease in FOXP3+Helios+ Treg frequency at the 6-month
time point (Fig. 3A); however, our secondary mechanistic
outcomes were not powered for immune subset analysis.
Nevertheless, several innate and adaptive subsets showed
intriguing trends in 12-month responders and 24-month
super responders (Supplementary Figs. 1 and 2 and Fig. 3).
Interestingly, the immune profile appeared to differ even
prior to study enrollment in the four super responders
versus non–super responders (Supplementary Fig. 1D and
Fig. 3A–D). Elevated monocyte HLA-DRMFI at the 6-month
time point may identify ATG+G-CSF 12-month nonre-
sponders (mean fold change = 1.6 relative to responders,
P , 0.01, two-way ANOVA with Sidák post hoc analysis)
(Supplementary Fig. 1A and Fig. 3E). Low HLA-DR MFI
among monocytes, high CD279 (PD-1) MFI among CD8+
effector memory RA (TEMRA) T cells, low naive CD4+
T-cell frequency, and low naive CD8+ T-cell frequency
may help identify ATG+G-CSF responders prior to treat-
ment (Supplementary Fig. 1C); however, these expression
Table 1—Changes (D) in metabolic outcomes reported as mean (SD) between the baseline and 24 months (D0–24), as well as
12- and 24-month (D12–24) evaluations.
ATG+G-CSF
(N = 16)
Placebo
(N = 8) P value*
ATG+G-CSF
P value**
Responders
(N = 9)
Nonresponders
(N = 7)
D Insulin requirement
(units/kg/day)
(D24–0) 0.110 (0.499) 0.207 (0.212) 0.68 0.127 (0.158) 0.0867 (0.783) 0.89
(D24–12) 0.084 (0.276) 0.102 (0.115) 0.19 0.182 (0.239) 20.074 (0.278) 0.11
D HbA1c (%)
(D24–0) 1.471 (3.105) 1.243 (1.385) 0.86 20.025 (0.883) 3.467 (3.953) ,0.05
(D24–12) 0.750 (2.329) 0.371 (0.720) 0.38 0.275 (0.857) 1.383 (3.498) 0.40
D C-peptide AUC
(nmol/mL/120 min)
(D24–0) 282.03 (166.0) 2150.3 (125.5) 0.13 210.46 (83.45) 2174.1 (205.0) ,0.05
(D24–12) 280.75 (121.3) 228.12 (117.6) 0.67 292.53 (65.80) 265.61 (174.7) 0.68
D C-peptide peak
(nmol/mL)
(D24–0) 20.996 (1.740) 21.599 (1.358) 0.40 20.281 (0.977) 21.916 (2.131) 0.06
(D24–12) 21.016 (1.273) 20.333 (0.891) 0.19 21.048 (0.936) 20.976 (1.696) 0.92
P values are calculated via Satterthwaite corrected t test for *Placebo vs. ATG+G-CSF total and **ATG+G-CSF responders vs.
ATG+G-CSF nonresponders.
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patterns and cellular subsets will need to be confirmed in
larger clinical cohorts.
Association Between Immunomodulation and
Preservation of b-Cell Function
We next asked whether persistent immunomodulatory
effects of ATG+G-CSF combination therapy correlated to
greater preservation of b-cell function. Indeed, we found
that among the 12-month responders, there was a significant
correlation between D C-peptide AUC and CD4+/CD8+ T-cell
ratios at the 6-month (Fig. 4A) (P , 0.05, R2 = 0.60) and
12-month (Fig. 4B) (P , 0.05, R2 = 0.53) time points.
Interestingly, nonresponders appeared to exhibit trends
toward inverse correlation between D C-peptide AUC and
CD4+/CD8+ T-cell ratio, although these were not statisti-
cally significant (Fig. 4A and B), which suggests that CD4+/
CD8+ T-cell ratios alone are likely not sufficient to discrim-
inate responders from nonresponders. Trends were observed
suggesting a positive association between FOXP3+Helios+ Treg
frequency and D C-peptide AUC at 6 months after the ini-
tiation of treatment (Fig. 4C), although the correlation was
most apparent among nonresponders and not statistically
significant (responders: P = 0.84, R2 = 0.04; nonresponders:
P = 0.08, R2 = 0.64); this trend did not persist to the
12-month time point (Fig. 4D). Indeed, this may suggest
that the long-term (i.e., 6- to 12-month) immunomodulatory
effects of ATG+G-CSF therapy are associated with greater
b-cell secretory capacity among responders, but given
the small sample sizes, confirmation with a larger cohort
is necessary.
Autoantibody Titers
We previously reported that treatment with ATG+G-CSF
did not significantly change autoantibody titers over the
course of the first year (12). We evaluated the change in
glutamic acid decarboxylase, insulinoma-associated protein
2, insulin, and zinc transporter 8 antibody titers from 12 to
24 months and again found no significant differences within
or between ATG+G-CSF or placebo treatment groups over
time (Supplementary Table 3).
AEs
AEs during the first 12 months were reported previously
(12). Importantly, in the second year following treatment,
few minor AEs were observed, and these occurred with
similar frequency and severity in both the ATG+G-CSF–
and placebo-treated groups. It was determined that these
AEs were unlikely to be attributable to therapy except
for one patient in the ATG+G-CSF treatment arm who
presented transiently with reduced CD4+ T-cell counts pos-
sibly related to treatment (Supplementary Table 4). Of
note, we saw no greater risk for infection or trouble clear-
ing infection in the ATG+G-CSF–treated group compared
with those assigned to the placebo arm. While potential
effects of antimicrobial treatment during the first 3 months
of ATG+G-CSF therapy have not been directly examined, we
do not consider persisting immunomodulation or preserva-
tion of C-peptide to be attributable to antimicrobial agents.
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CONCLUSIONS
Efforts to reverse type 1 diabetes in human subjects have
varied widely regarding immunological or metabolic targets
(reviewed in refs. 2,19), and it is clear that a combination
approach will be necessary to halt autoimmunity and maintain
b-cell mass. This notion is perhaps best supported by the
efforts of Voltarelli et al., Li et al., and Snarski et al., in which
an aggressive approach involving autologous nonmyeloablative
Figure 2—Immunomodulatory effects of ATG+G-CSF combination therapy remain detectable at least 24 months following treatment.
PBMCs were characterized by flow cytometric analysis, and complete blood count was performed. Compared with placebo (gray squares;
N = 8), subjects treated with ATG+G-CSF (black circles; N = 16) exhibited reduced CD4+ T-cell frequency (A), increased CD8+ T-cell
frequency (B), and reduced CD4+/CD8+ T-cell ratio (C ). D: CD4+CD25+FOXP3+Helios+ Tregs were significantly elevated in ATG+G-CSF–
treated subjects at 6 and 12 months, but the difference was not significant at 24 months. CD4+ Tem frequency (E ), CD16+CD56hi NK
percent (F ), CD4+PD-1+ Tcm frequency (G), PD-1 MFI on CD4+ Tcm (H), and neutrophil counts (I) were significantly greater in ATG+G-CSF–
treated subjects compared with control subjects. All P values shown are for ATG+G-CSF vs. placebo at the indicated time points.
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stem cell transplant along with cyclophosphamide, G-CSF,
and high-dose ATG provided a period of insulin indepen-
dence in most patients (5–8). More recently, similar re-
sults were reported in a small cohort of patients with type
1 diabetes who, in an outpatient setting, underwent au-
tologous stem cell transplantation with G-CSF, cyclophos-
phamide, and the chemotherapeutic agent fludarabine in
place of ATG (20). Ultimately, the associated risks and
observed adverse effects preclude implementation of
these treatment protocols as standard of care, especially
in children and adolescents. Nevertheless, these results
represent progress in the field and a platform for our
recent studies. Efforts to utilize a single agent from this
combination therapy, either ATG alone or G-CSF alone,
have not met with success. However, in the START trial, the
older ATG-treated subjects appeared to fare far better with
slower rate of b-cell loss than adults in the placebo group or
ATG-treated adolescents (9,10). No immunological study
accounted for these apparent treatment differences.
We administered low-dose ATG plus pegylated G-CSF
to patients with established type 1 diabetes, and although
subjects did not experience clinical remission, we observed
significant preservation of b-cell function for 12 months
following treatment (12). At 24 months, b-cell function
appears to remain greater in ATG+G-CSF–treated patients
compared with those that received placebo, but in this
small cohort, the difference was no longer statistically
significant. Mechanistically, a number of immunologi-
cal parameters were altered as result of ATG+G-CSF
treatment—CD4+ T-cell frequency was reduced while CD8+
T-cell frequencies increased, resulting in reduced CD4+/CD8+
T-cell ratios. Additionally, FOXP3+Helios+ Treg, CD4+ Tem,
CD16+CD56hi NK, and CD4+PD-1+ Tcm frequencies, as well
as Tcm PD-1 expression levels and neutrophil counts, were
significantly elevated in ATG+G-CSF–treated subjects com-
pared with those that received placebo. Importantly, these
therapeutic effects were sustained even 24 months from the
time of treatment with the exception of increased Treg fre-
quency in treated patients, which was only detectable through
the first 18 months. These data suggest that ATG+G-CSF
combination treatment imparts prolonged immunomodula-
tory effects, although with small sample sizes reported here,
these results are exploratory and need to be confirmed.
We previously reported that within the ATG+G-CSF
treatment group, nine responders maintained or even
improved their capacity for insulin production over the
first 12 months following treatment while MMTT-
stimulated C-peptide AUC fell below baseline values in the
remaining seven nonresponders (12). At 24 months, these
responders still demonstrated a trend toward higher
C-peptide AUC compared with nonresponders. With age
as the only demographic factor differentiating these two
groups (responders were older than nonresponders by a
mean difference of 9.95 years, P , 0.05) (12), there is a
need for further studies including larger cohorts to inves-
tigate potential biomarkers or genetic haplotypes that
might help us to better predict patients as strong candi-
dates for ATG+G-CSF combination therapy. Interestingly,
both ATG+G-CSF combination treatment tested here as
well as ATG monotherapy are more efficacious in older
patients in situations of both new-onset and established
disease (9,12). A subgroup of four super responders with
C-peptide AUC greater than baseline at the 24-month
time point were identified, but the small sample size pre-
cluded statistical analysis of immune markers or potential
age-related effects. Collectively, these data suggest that
immune profiles may identify candidates for such ther-
apy, albeit validation in a larger cohort is clearly neces-
sary. Further studies are needed to accurately determine if
T cells are moving to a more anergic/senescent phenotype
following ATG+G-CSF therapy, as has been observed with
other T cell–targeting agents that have demonstrated clin-
ical responses (21,22).
Figure 2—Continued.
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The notion of responders and nonresponders implies
that some patients may be refractory to certain therapies,
likely representing differences in genetics, physiology,
and/or disease pathogenesis. Alternatively, patients may be
effective immunological responders without a recovery of
endogenous b-cell mass or function. This is an important
phenomenon not only from the perspective of clinical prac-
tice but also in clinical trials where, on first analysis,
Figure 3—Peripheral blood immune cell populations were characterized by flow cytometric analysis in ATG+G-CSF 24-month super
responders (black circles; N = 4) vs. non–super responders (gray squares; N = 12). There were no significant differences in Treg (A),
CD16+CD56hi NK (B), or CD8+PD-1+ Tcm (C) frequency change from baseline, but there was a trend toward reduced CD4+ Tcm PD-1 MFI
change (D) from baseline in super responders at the 12-month time point. E: HLA-DR MFI on monocytes was significantly elevated in
ATG+G-CSF 12-month nonresponders (gray squares; N = 7) compared with responders (black circles; N = 9) at the 6-month time point. In
12-month responders vs. nonresponders, there were no significant differences in CD4+/CD8+ T-cell ratio (F), FOXP3+Helios+ Treg
frequency (G), or CD16+CD56hi NK percent (H) at all time points evaluated.
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nonresponders may mask statistically and biologically sig-
nificant effects of a given therapy in the responder
group. Moving forward, further investigation is needed
to identify biomarkers differentiating these patient pop-
ulations so that we can better predict those who will
benefit from treatment. While not adequately powered
for subset analysis in this initial trial, our immune pro-
filing of responders demonstrated a trend toward low
monocyte expression of HLA-DR (an antigen-presenting
cell activation marker) at baseline, as well as high expres-
sion of the negative regulator PD-1 on CD8+ effector mem-
ory RA T cells as potential immune biomarkers of response.
Importantly, significant positive correlation between CD4+/
CD8+ T-cell ratios and D C-peptide AUC was observed
among responders at 6 and 12 months after beginning
treatment, suggesting that long-term immunoregulation is
associated with greater preservation or recovery of b-cell
secretory capacity. However, from these data we cannot de-
finitively ascertain if this represents a causal relationship.
It remains to be determined whether earlier inter-
vention with ATG+G-CSF in subjects with recent-onset
type 1 diabetes (duration ,4 months) may offer improved
efficacy (23). This concept is currently being explored in the
National Institutes of Health (NIH)-funded Type 1 Diabe-
tes TrialNet utilizing a three-arm trial of 1) low-dose ATG
alone, 2) low-dose ATG+G-CSF, and 3) placebo in pa-
tients with new-onset disease (ClinicalTrials.gov identifier
NCT02215200). Repeat dosing of ATG+G-CSF or G-CSF,
potentially in combination with autoantigen vaccination,
is an additional concept that might promote continued
immune regulation for prolonged elevated Treg frequency
and extended preservation of endogenous b-cell function.
In addition to ATG+G-CSF, combinatorial agents promoting
b-cell regeneration or islet transplant may be necessary to
provide recovery of functional b-cell mass in subjects with
established disease. Indeed, we previously reported a four-
drug combination treatment that was able to reverse not
only new-onset diabetes but even established disease in the
NOD model (24) using low-dose ATG+G-CSF plus dipep-
tidyl peptidase 4 inhibitor and proton pump inhibitor.
These two additional agents have together afforded effi-
cacy in preclinical type 1 diabetes studies (25), are already
Figure 4—Immmunomodulatory effects of ATG+G-CSF combination therapy were associated with MMTT-stimulated C-peptide AUC
change from baseline in 12-month responders (blue; 12-month C-peptide AUC > baseline) and nonresponders (orange; 12-month
C-peptide AUC < baseline). For responders, Δ C-peptide AUC significantly correlated with CD4+/CD8+ T-cell ratios at 6 months (P <
0.05, R2 = 0.60) (A) and 12 months (P < 0.05, R2 = 0.53) (B) following treatment, and nonresponders demonstrated trends toward inverse
correlation (A: P = 0.24, R2 = 0.01; B: P = 0.30, R2 = 0.33). Nonresponders demonstrated a trend toward positive correlation between
FOXP3+Helios+ Treg frequency and D C-peptide AUC at 6 months (nonresponders: P = 0.08, R2 = 0.64; responders: P = 0.84, R2 = 0.04)
(C), but no associations were observed between FOXP3+Helios+ Treg frequency and D C-peptide AUC at 12 months (nonresponders: P =
0.50, R2 = 0.23; responders: P = 0.79, R2 < 0.01) (D).
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approved by the U.S. Food and Drug Administration for use
in treating type 2 diabetes and gastroesophageal reflux
disease, and are commonly prescribed in the clinic with
low associated risks. Keeping in mind the importance of
equipoise, we expect that a similar approach using the
immunomodulatory combination of ATG+G-CSF along
with these or other methods for b-cell replacement
and/or regeneration may provide a means to improve
metabolic control and slow autoimmune b-cell destruction
in human subjects with type 1 diabetes.
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